金奧博(002917.SZ):目前合計擁有工業炸藥年許可生產能力11.5萬噸
格隆匯12月21日丨金奧博(002917.SZ)近期在接待機構投資者調研時表示,為優化整合科研和生產資源,促進公司產業鏈的有效延伸,公司併購重組了江蘇天明化工、山東聖世達、京煤集團有關民爆資產及山東泰山民爆等民爆生產企業,目前合計擁有工業炸藥年許可生產能力11.5萬噸,數碼電子雷管年許可生產能力8522萬發,以及保留導爆管雷管、工業電雷管年許可生產能力4000萬發用於出口。公司目前產能利用率總體良好,同時產能利用率是一個動態過程,受市場及生產組織安排等多方面影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.